RSLS News and Press, ReShape Lifesciences Inc. From 11/11/22

ReShape Lifesciences ( NASDAQ: RSLS ) is scheduled to announce Q3 earnings results on Monday, November 14th, before market open. The consensus EPS Estimate is -$0.35 and the consensus Revenue Estimate is $3.62M (-2.2% Y/Y). Over the last 3 months, EPS estimates have se...

ReShape Lifesciences ( NASDAQ: RSLS ) shares fell over 10% on Tuesday after the health solutions company announced a $750,000 securities offering. The company entered into a securities purchase agreement with a single institutional investor for the purchase and sale of...

SAN CLEMENTE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has entered into a securities purchase agreement with a single institutional investor for t...

SAN CLEMENTE, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 202...

SAN CLEMENTE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the presentation of data on its proprietary Diabetes Bloc-Stim Neuromodulation!...

SAN CLEMENTE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chi...

Lap-Band ® is the Only FDA Approved Device Indicated for Weight Reduction in Patients With a Body Mass Index (BMI) of at Least 40 kg/m 2 or a BMI of at least 30 kg/m 2 With One or More Obesity-Related Comorbidities Updated Guidelines Recommend Me...

Data Shows ReShape’s DBSN™ System has Promise as a Novel, Adjustable and Localized Approach to Treat Type 2 Diabetes SAN CLEMENTE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight los...

Active ASMBS Members, Comprised of Lap-Band ® Clinical Experts, Participated in a Consensus Process to Yield Recommendations for Optimal Aftercare ASMBS Reasserts Endorsement of the Lap-Band ® as a Safe and Effective Weight Loss Procedure SAN CLEMENTE, Ca...

SAN CLEMENTE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded a $300,000 Small Business Innovation Research (SBIR) ...